REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (ROXI-ASPEN)
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
Sponsor: Regeneron Pharmaceuticals
Listed as NCT07213778, this observational or N/A phase trial focuses on Symptomatic Venous Thromboembolism (VTE) and remains actively recruiting participants. Sponsored by Regeneron Pharmaceuticals, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .